Malignancies of the head and neck: The role for molecular targeted agents

Mark Agulnik*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Although cancers arising in the head and neck region are a diverse group of malignancies, a unifying thread remains a poor overall survival for patients with advanced, recurrent or metastatic disease. Treatment strategies need to evolve and improve upon established therapeutic practices. As the process of cancer evolution is understood to be derived from aberrations in genetic and epigenetic processes, molecularly targeted agents offer attractive therapeutic options by restoring normal control of oncogenic processes. The direct role for the treatment of squamous cell carcinoma of the head and neck, nasopharynx and salivary gland carcinomas with these novel, molecularly targeted agents are reviewed and their potential to improve on the existing standard of care is further explored.

Original languageEnglish (US)
Pages (from-to)207-217
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Issue number2
StatePublished - Feb 2007


  • Head and neck neoplasm
  • Investigational therapy
  • Nasopharyngeal neoplasm
  • Salivary gland neoplasm

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Malignancies of the head and neck: The role for molecular targeted agents'. Together they form a unique fingerprint.

Cite this